NEXTHERA Capital Strengthens Investment And Operational Team
Long/short equity healthcare fund NEXTHERA Capital today announced the strengthening of its investment and operations team with two hires and two promotions.
The hires include Menka Lamba, who joins as head of marketing and investor relations, and Sal Rais, who was recruited to join as a healthcare analyst. Lamba has over 15 years of industry experience at firms such as Highland Capital, Bay Harbour and FrontPoint Partners. Rais is former Balyasny Asset Management healthcare analyst; these hires bring the investment team to seven professionals and the wider team to 12 people.
Additionally, Rael Mazansky, director of research and former portfolio manager at Surveyor Capital (Citadel), has been promoted to partner and portfolio manager of biotechnology. CFO and COO Tim Surzyn, formerly a senior member of the UBS Prime Brokerage Capital Consulting team, was also named a partner.
“These key personnel hires and promotions are important investments in human capital and they will further enhance the institutional offering we provide to investors” said Daniel Malek, CEO and co-founder of NEXTHERA.
Heading further into 2018, NEXTHERA outlined important investment opportunities in the large cap pharmaceuticals, generics/specialty pharma and biotechnology sectors that can set the stage for extended growth and performance.
“We continue to remain highly positive on the cycle of innovation in biotechnology, a favorable regulatory environment, and the potential for industry consolidation and M&A, while remaining cautious on the pricing pressure and commoditization in large-cap pharmaceuticals and generics.”
NEXTHERA was launched in July 2015 by Daniel Malek and Ori Hershkovitz with $95 million, and currently manages $388 million between a flagship hedge fund and UCITS product, which joined the Geneva based Union Bancaire Privée UCITS platform last year.